首页> 美国卫生研究院文献>other >Direct quantification of microRNA at low pM level in sera of glioma patients using a competitive hybridization followed by amplified voltammetric detection
【2h】

Direct quantification of microRNA at low pM level in sera of glioma patients using a competitive hybridization followed by amplified voltammetric detection

机译:在脑胶质瘤患者血清中低级别时使用竞争性杂交的microRNa的直接定量然后放大伏安检测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MicroRNAs (miRNAs), acting as oncogenes or tumor suppressors in humans, play a key role in regulating gene expression and are believed to be important for developing novel therapeutic treatments and clinical prognoses. Due to their short lengths (17–25 nucleotides) and extremely low concentrations (typically < pM) in biological samples, quantification of miRNAs has been challenging to conventional biochemical methods, such as Northern blotting, microarray, and quantitative polymerase chain reaction (qPCR). In this work, a biotinylated miRNA (biotin-miRNA) whose sequence is the same as that of a miRNA target is introduced into samples of interest and allowed to compete with the miRNA target for the oligonucleotide (ODN) probe preimmobilized onto an electrode. Voltammetric quantification of the miRNA target was accomplished after complexation of the biotin-miRNA with ferrocene (Fc)-capped gold nanoparticle/streptavidin conjugates. The Fc oxidation current was found to be inversely proportional to the concentration of target miRNA between 10 fM and 2.0 pM. The method is highly reproducible (RSD < 5%), regenerable (at least 8 regeneration/assay cycles without discernible signal decrease) and selective (with sequence specificity down to a single nucleotide mismatch). The low detection levels (10 fM or 0.1 attomoles of miRNA in a 10-HL solution) allow the direct quantification of miRNA-182, a marker correlated to the progression of glioma in patients, to be performed in serum samples without sample pretreatment and RNA extraction and enrichment. The concentration of miRNA-182 in glioma patients was found to be 3.1 times as high as that in healthy persons, a conclusion in excellent agreement with a separate qPCR measurement of the expression level. The obviations of the requirement of an internal reference in qPCR, simplicity, and cost-effectiveness are other additional advantages of this method for detection of nucleic acids in clinical samples.
机译:微小RNA(miRNA)作为人类的癌基因或肿瘤抑制因子,在调节基因表达中起关键作用,并被认为对于开发新型治疗方法和临床预后很重要。由于它们的长度短(17–25个核苷酸)且在生物样品中的浓度极低(通常M),因此对常规生物化学方法(如Northern印迹,微阵列和定量聚合酶链反应(qPCR))的miRNA定量提出了挑战。 。在这项工作中,将序列与miRNA靶序列相同的生物素化miRNA(biotin-miRNA)引入目标样品中,并与miRNA靶竞争预先固定在电极上的寡核苷酸(ODN)探针。生物素-miRNA与二茂铁(Fc)封端的金纳米颗粒/链霉亲和素偶联物复合后,完成了miRNA靶的伏安定量。发现Fc氧化电流与目标miRNA的浓度成反比,介于10 fM和2.0 pM之间。该方法具有高度可重复性(RSD <5%),可再生(至少8个再生/测定循环,而信号信号未见下降)和选择性(序列特异性低至单个核苷酸错配)。低检测水平(10-HL溶液中的miRNA的10 fM或0.1原子)可直接在血清样品中进行miRNA-182(与患者脑胶质瘤进展相关的标记)的直接定量,而无需样品预处理和RNA提取和浓缩。发现神经胶质瘤患者中miRNA-182的浓度是健康人的3.1倍,这一结论与单独的qPCR表达水平测定非常吻合。无需在qPCR中使用内部参照物,简便性和成本效益是该方法用于临床样品中核酸检测的其他其他优点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号